Fact CheckerSign in

NCT07911787Not yet recruitingPhase 3

Phase 3 Study of HS-10380 for Acute Schizophrenia in Chinese Adults

A Randomized, Double-Blind, Active- and Placebo-Controlled Phase 3 Clinical Study Evaluating the Efficacy and Safety of HS-10380 in Chinese Adult Patients With Acute Schizophrenia

Source: ClinicalTrials.gov · Last updated 3 Nov 2026

Brief summary (registry, in English)

This is a Phase 3, randomized, double-blind, parallel-group, active- and placebo-controlled, multicenter inpatient study to examine the efficacy and safety of HS-10380 in adult Participants who are acutely psychotic with a Diagnostic and Statistical Manual Fifth Edition (DSM-5) diagnosis of schizophrenia. The primary objective of the study is to assess the efficacy of HS-10380 versus placebo in reducing Positive and Negative Syndrome Scale (PANSS) total scores in adult inpatients with a DSM-5 diagnosis of schizophrenia. The secondary objectives of the study are to evaluate the response rate, improvement in disease severity and symptoms, safety and tolerability.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 3
Study type
Interventional
Enrollment
476 (estimated)
First submitted
28 Oct 2026
Start date
4 Nov 2026
Primary completion date
24 Jan 2029
Lead sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT number
NCT07911787

What you commit to

  • Study type: Interventional · Phase 3
  • Planned participants: 476
  • From 4 Nov 2026 to the primary completion date, 24 Jan 2029
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • History of drug abuse within 1 year prior to screening.
  • History of alcohol abuse within 6 months prior to screening.

Other illness

  • History or presence of clinically significant neuropsychiatric, cardiovascular, urinary, digestive, respiratory, musculoskeletal, metabolic/endocrine, hematological, immune, dermatological, and oncological systems disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results.
  • History of epilepsy (except febrile convulsions) or neuroleptic malignant syndrome.
  • Any surgical condition or medical condition that may significantly affect drug absorption, distribution, metabolism, and excretion, or that may pose a risk to trial participants, such as history of gastrointestinal surgery (gastrectomy, gastroenterostomy, bowel resection, etc.), urinary tract obstruction, or dysuria.
  • History of severe allergic reactions.

Lab values

  • Abnormal laboratory parameters at screening or baseline.

Other

  • Judged by the investigator as having treatment-resistant schizophrenia.
  • Patients with risk of violent or destructive behavior, or suicidal risk.
  • Female patients who are pregnant, in puerperium, or lactating at screening or baseline.
  • Abnormal vital signs at screening or baseline.
  • Abnormal 12-lead ECG at screening or baseline.

Who the study is looking for

  • Participant is aged 18-65 years, inclusive, at screening.
  • Body mass index must be ≥18.0 and ≤40.0 kg/m² at screening.
  • Participant has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the DSM-5 criteria and confirmed by Mini International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorder Studies (MINI) version 7.0.2.
  • Positive and Negative Syndrome Scale total score between 80 and 120, inclusive, at screening or baseline Score of ≥ 4 (moderate or greater) for ≥ 2 of the following Positive Scale (P) items at screening: Item 1 (P1; delusions)\\Item 2 (P2; conceptual disorganization)\\Item 3 (P3; hallucinatory behavior)\\Item 6 (P6; suspiciousness/persecution) .

Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Shanghai Mental Health Center
Coordinator of this site? Confirm its status
ShanghaiChinaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.